Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®

NCT01731028 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2013-02-01

No results posted yet for this study

Summary

The purpose of this study is to investigate the long-term treatment with Zomacton® for pituitary short stature in children with insufficient growth hormone production and/or short stature caused by Turner's syndrome.

Conditions

  • Growth Hormone Deficiency

Interventions

DRUG

Somatropin

Somatropin powder and solvent for solution for injection

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2017-12-31
Completion
2018-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01731028 on ClinicalTrials.gov